Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

MGC Pharmaceuticals' proprietary ZAM app "about good practice"

MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements speaks to Proactive's Thomas Warner after announcing the enrolment of the first patient in its proprietary data collection App and machine learning algorithm, ZAM. Clements explains why MGC is investing in medical technology, saying that "this is about good practice." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 27, 2023 03:00 AM Eastern Daylight Time

Video

Goodbody Health takes "next step" into blood testing market

Goodbody Health Ltd

Goodbody Health Ltd (AQSE:GDBY, OTCQB:GDBYF) group CEO George Thomas speaks to Proactive after launching a new platform that he describes as the "Uber for mobile phlebotomy." Thomas reveals more about the market opportunity for the new service, adding that it represents the "next step" into the blood testing market for the UK-based aggregator of health and wellness products and services. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 27, 2023 03:00 AM Eastern Daylight Time

Video

News Release

Rakovina Therapeutics receives government grant to accelerate novel cancer therapy program

Rakovina Therapeutics Inc

Rakovina Therapeutics chief scientific officer Mads Daugaard joined Proactive's Steve Darling to share news the company is receiving research and development funding from the National Research Council of Canada Industrial Research Assistance Program. Daugaard tells Proactive the non-dilutive financing will provide its scientists in the development of DNA-damage response inhibitors with the goal of selecting one or more lead compounds for advancement to either toxicology and/or investigational new drug studies. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

March 24, 2023 01:46 PM Eastern Daylight Time

Video

News Release

HealthLynked new wireless technology patent adding more patient benefits through digital healthcare

HealthLynked

HealthLynked CEO Dr Michael Dent joins Proactive's Natalie Stoberman to discuss the company's latest patent for "Secure Patient Access via Healthcare Service Provider Specific Wireless Access Point” technology. Dent says the patented technology encompasses systems and methods for providing a healthcare service provider-specific wireless access point, or 'HUB', that facilitates secure communication between patients, providers, and third-party services. When in range of the HUB, such as in a doctor’s office waiting room, patient devices can connect to the healthcare service provider’s wireless access point. The access point can then be configured to detect the presence of a patient device, obtain identifying information, and send the information to a server to facilitate a layer of digital healthcare. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

March 24, 2023 01:22 PM Eastern Daylight Time

Video

Applied UV's Devices Effective Against Dangerous Pathogen Candida Auris As CDC Warns Of Rapid Spread In US Healthcare Facilities

Applied UV, Inc.

Applied UV, Inc. (NASDAQ: AUVI) recently announced that the Center of Disease Control (CDC) has warned that Candida Auris (C. auris) is spreading rapidly through U.S. healthcare facilities. As the company previously announced, the Sterilumen family of disinfection devices was independently tested by ResInnova Laboratories (an independent microbiology testing laboratory specializing in antimicrobial technologies) who confirmed that the Company’s devices kill C.auris on sink handles, achieving a log2 kill in just fifteen minutes of operation. Applied UV’s recently acquired Puro UV completed independent lab testing commissioned by Violet Defense ™, the UV technology provider powering Puro’s Helo products, and performed at an EPA and FDA GLP-compliant, ISO 17025 Accredited Testing Laboratory. Testing determined that Puro UV disinfecting fixtures are effective at killing the C. auris fungus. Sterilumen’s complete family of air and surface disinfection devices including Airocide® Air Purification System, a proprietary airborne pathogen killing technology originally developed for use by NASA and listed as a FDA Class II Medical Device that uses a patented combination of UVC and a proprietary, titanium dioxide based photocatalyst, kills the emerging multi-drug resistant fungus, Candida auris (“C. auris”) as well as its surface disinfection platform Lumicide. Additionally, independent research previously conducted demonstrated that Airocide® also kills MRSA (methicillin-resistant Staphylococcus aureus). Applied UV‘s patented LumiCide Surface and Drain UVC Disinfecting Systems is currently installed within the world renowned Mt. Sinai Medical Center Morningside in a trial, the results of which are expected to be published late in Q3 2023 which would further validate the previously obtained independent results conducted by ResInnova Laboratories. This validation could facilitate the adoption of the Company’s LumiCide Surface and Drain disinfection solutions throughout healthcare facilities globally. Mount Sinai Morningside, formerly known as Mount Sinai St. Luke's, is a teaching hospital located in the Morningside Heights neighborhood of Manhattan in New York City. Mount Sinai Morningside is affiliated with the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System, a nonprofit hospital system formed by the merger of Continuum Health Partners and the Mount Sinai Medical Center in September 2013. It provides general medical and surgical facilities, ambulatory care, and a Level 2 Trauma Center, verified by the American College of Surgeons. It operates 21 clinics and as of 2020, is nationally ranked by U.S. News & World Report. Candida auris is an emerging fungal pathogen that presents a serious global health threat. It enters the body through the skin and infects the bloodstream, central nervous system, and multiple internal organs. It has been identified as being multiple drug resistant, and the disease is particularly pernicious in patients with weakened immune systems, which is why it is so problematic in hospitals and long-term care facilities. “CDC“ currently considers Candidiasis as one of the most significant infectious diseases in the world today. Applied UV’s LumiCide Disinfection System product line has the following attributes: Focus on the sink area and drain. Focuses on pathogens that accumulate on the sink area, including handles, faucets and backsplash and in the drain. UVC LED Pathogen Destruction. Destroys 4 logs (99.99%) some of the most dangerous pathogens like COVID 19, MERSA C’diff, in the bathroom vanity/sink area with at least two hours of continuous use. Automatic operation. Built-in programmable controller that ensures operation for the full required daily time and is not dependent on manual operation. Continuous operation. Works in cycles of two hours on and four hours off, except for the disinfecting drain which is on 15 minutes every hour. The timing protocol is managed by a programmable controller and a motion detector enclosed within each device and works while the room is still occupied and while the bathroom is not in use, therefore, continuously disinfecting an area of ongoing high contamination. Safety. Built-in motion detector and sensor automatically shuts off the UVC light when anyone enters the room eliminating any concern over UV safety. Once there is no movement in the room for 10 minutes the UVC light comes back on to restart and continue its cycle. Removable UVC LED panel. The UVC LEDs are installed via a removable panel, leading to ease of replacement or upgrade. Ease of Installation. The unit is easy to install and uses standard electrical wiring. IOT connectivity. IOT connectivity uses Wi-Fi and RF technology that enables continuous transmission of use and functionality data over the Internet for collection and analysis. Applied UV’s internal research and research provided by the CDC estimates that each year about one in 25 U.S. hospital patients (approximately 1.4 million people) are diagnosed with at least one infection related to hospital care alone and additional infections occur in other healthcare settings. Approximately 900,000 Americans die each year due to complications associated with Hospital Acquired Infections (“HAI”). Many HAI’s are caused by the most urgent and serious antibiotic-resistant (AR) bacteria and my lead to sepsis or death. According to NIH, Healthcare-associated infections are known to increase the length of stay, healthcare costs, and mortality. Each year the top five healthcare-associated infections result in about $9.8 billion in costs. Applied UV is focused on the development and acquisition of technology that addresses infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s Airocide® air purification devices are research-backed, clinically proven, and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photo-catalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors, and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine-making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities, and homes. SteriLumen’s connected platform for Data-Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company’s Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices’ proximity. The Company’s patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen-intensive location. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Brett Maas- Hayden IR brett@haydenir.com Company Website https://www.applieduvinc.com/

March 24, 2023 09:25 AM Eastern Daylight Time

UAT Group’s Subsidiary, H2O Processing, Submits Proposal to Texas Railroad Commission

Umbra Applied Technologies Group, Inc.

McapMediaWire -- Umbra Applied Technologies Group, Inc's (OTC: UATG ) subsidiary, H2O Processing, announced today that, at the request of The Texas Railroad Commission (“TRC”), it has submitted a proposal to support a pilot program designed to treat and reduce wastewater currently being disposed of in salt water discharge wells. The objective of the TRC’s program is to not only reduce the amount of discharge water, but to address the amount of seismic activity in the Permian basin. H2O has developed a proprietary process to significantly reduce the volume of water injected in to salt water discharge (SWD) wells. The process can: 1. Treat the water to a quality that can be used for agricultural use. 2. Treat high salinity water by separating the salt and reducing the remaining byproduct for disposal to approximately 10%. 3. The separated salt can be captured and marketed as a commodity. The H2O proposal outlines the use of a 200 gallons per minute system (6,700 BBls/day) and includes a mechanical evaporation unit to treat water where the chlorides are above 60,000 ppm. H2O believes this system will properly demonstrate the viability of the process. Once this pilot project is completed then, H2O can work with the TRC for larger systems to be deployed to treat larger volumes of water in various areas identified by the TRC. The systems are portable and can be used in different locations in order to prove the ability to treat different waters from different locations and wells. H2O Processing Chief Executive Officer, Stan Abrams stated,” We are very excited to team up with and support the efforts of the Texas Railroad Commission. My team and I are looking forward to working with the Commission and the great State of Texas”. H2O’s evaporation process is a mechanical system that will produce a “clean salt” that is less than 10% moisture. The salt can be processed into several products to meet a large demand and market. The salt commodity can be marketed and removed from the process sites and converted into an income-producing product instead of a waste product to be injected in to a SWD. H2O Processing’s proprietary system treats high percentage chlorides in water so that the final ratio of wastewater is reduced by as much as 90%. The proposed system can also recapture water through the evaporation process via a condensation system. Water recaptured in a condensation process would be high-quality water and 100% reusable. H2O Processing is a manufacturing, research, and engineering company, with extensive experience in the water treatment industry. With an expanding portfolio of intellectual property, the H2O team has just recently begun its expansion as a full provider and manufacturer of mobile on-site and fixed commercial water treatment platforms. H2O Processing’s mobile water treatment platform concluded field testing within Oklahoma and has been awarded the only state-wide permit in all 77 counties, to treat deleterious water to non-deleterious water. The mobile platforms are fully automated and can be managed remotely by either H2O Processing from their headquarters in Denver or managed by an onsite team. The mobile platform is ready for commercial production and is now being delivered into the market. Chairman of H2O Processing parent company, UAT Group, Alex Umbra commented, “This proposal, once accepted, carries a significant environmental impact potential that is unrivaled in this segment. Once again, H2O and UAT Group, continue to further demonstrate their shared commitment to the environment and bringing forth responsible technology that brings value to our customers as well as our shareholders”. The Company continues to work on non-dilutive financing to build and construct their proprietary Iron Removal Systems for the oil industry as outlined in prior news releases. The recent turmoil in the US banking industry resulting from the collapse of the Silicon Valley Bank has slowed our progress but we remain optimistic that this will be achieved as well. For more information about H2O Processing, Inc. visit: https://h2oprocessing.com/ For more information visit www.uatgroup.com Investor and Media Contact: info@uatgroup.com About H2O Processing, Inc. The Company is located in Denver, CO, and is an advanced water and oil treatment technology company. NEITHER THE SECURITIES EXCHANGE COMMISSION NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE. Forward-Looking Information This news release may include "forward-looking statements" including forecasts, estimates, expectations, and objectives for future operations including but not limited to its ability to conclude a business combination with a third party, sale of assets, return of capital or initial public offering and/or a secondary listing as a result of aforementioned and its ability to fund the exploration of its assets through the raising of equity or debt capital or through funding by a joint venture partner that are subject to a number of assumptions, risks, and uncertainties, many of which are beyond the control of H2O Processing including but not limited to capital markets and securities risks and continued development success on technology. There can be and are no actual or implied guarantees that any of the above activities will be completed or completed on terms acceptable to the Company and its shareholders or approved by any regulatory authority having jurisdiction. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. H2O Processing does not assume the obligation to update any forward-looking statement, except as required by applicable law. Contact Details UAT Group info@uatgroup.com

March 24, 2023 08:30 AM Eastern Daylight Time

Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development

Coya Therapeutics Inc.

By David Willey, Benzinga Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India. Through this partnership, Coya will license Dr. Reddy’s biosimilar product, Abatacept, allowing Coya to develop its combination product, COYA 302. This drug will combat various neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS). Through its one-time, non-refundable fee, Coya has an exclusive and royalty-bearing license to Abatacept for the development and commercialization of COYA 302. This license also gives Coya the right to sell the drug in the Americas, the EU, the United Kingdom, Japan and elsewhere, and Coya will owe royalties to Dr. Reddy for the sale of the product. In addition, Dr. Reddy’s will develop COYA 302 in its own territories and will owe royalties back to Coya upon the commercialization of COYA 302. COYA 302 is a dual biologic product that will provide a novel treatment for various neurodegenerative diseases. Using the components COYA 301 and CTLA4-Ig, the drug suppresses inflammation in the brain or spinal cord via the body’s immunomodulatory pathways. Coya expects to file an investigational new drug (IND) application with the Food and Drug Administration (FDA) in the second half of 2023, with a phase 1b/2 trial to follow. Why This Deal Matters For Future Drug Development This partnership, between a multi-billion generic drug company and a small biotech, is amongst the first of its kind. It could indicate a shift in how major drug companies are positioning their development pipeline, as they explore a biologic biosimilar’s ability to treat new indications, or symptoms, for major diseases. The global biosimilar market has seen recent growth, with North America making up the largest portion of the market. The market was worth $28.61 billion in 2021 and is predicted to reach $103 billion by 2028, growing by a compound annual growth rate (CAGR) of 25.6% during the forecast period of 2022-2028. There are already 33 FDA-approved biosimilars that are used in various treatments including for cancer and autoimmune diseases. As well as improving treatments, biosimilars have already helped bring the cost of medication down. Dr. Reddy is a leading player in the biosimilar market. The partnership it entered with Coya signals that Dr. Reddy is adopting a new and possibly transformative approach to biosimilars. By combining a biologic biosimilar with another drug product, it is adapting the potential of biosimilars so they can treat new symptoms of serious diseases. Coya is already developing a Treg-based therapy to deal with neurodegenerative diseases with its Coya-101 product. Now, through its partnership with Dr. Reddy, Coya is showcasing the exciting potential of collaborations between smaller biotech companies and billion-dollar pharmaceutical corporations. Coya already has compelling early data from its clinical trials for COYA 302, and it will be revealing the data at the Muscular Dystrophy Association (MDA) conference on March 21st. Other biologics companies include Eli Lilly and Company (NYSE: LLY), bluebird bio (NASDAQ: BLUE) and GeoVax, Inc. (NASDAQ: GOVX). This article was originally published on Benzinga here. About Coya Therapeutics, Inc.Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages. These two mechanisms may be additive or synergistic in suppressing inflammation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice Contact Details David S. Snyder David@coyatherapeutics.com Company Website https://coyatherapeutics.com/

March 23, 2023 09:15 AM Eastern Daylight Time

Kim Sledge of Sister Sledge, the recording artists behind the international hit song “We are Family” Urges Support for The American Center for Cures

The American Center for Cures

Kim Sledge of Grammy Award winning vocal group Sister Sledge, famed for its international hit song and platinum album, “We are Family,” advocated her support for The American Center for Cures (ACC), an audacious “moonshot” mission to prevent, treat or cure diseases that plague every American family, with a new song titled, “ Unity Strong.” Ms. Sledge also shared personal commentary in support of the ACC: “I’m Kim Sledge from the recording group Sister Sledge. We recorded the international hit song, ‘We Are Family.’ I write today in support of The American Center for Cures. Having had the privilege of traveling around the world and looking in the eyes of people of all colors, ages, and cultures, and having seen both healthy, as well as, unfortunately disease affected communities, I am in full support of an initiative I was introduced to by a very dear friend of our families, Mr. Lou Weisbach, CEO and Co-Founder of ACC. Lou, Ruthie, and their family have, over the years, shared in and supported some of my family’s great times and losses. To think that some of those sad times could have been avoided, but even more to know, now there’s a new hope, and soon other families won’t have to go through the despair of disease and loss. I am truly grateful and ecstatic to hear of the possibilities The American Center For Cures has planned. Its mission is awe inspiring and I believe it is divinely designated for such a time as this. Globally, we are in dire and imminent need of a fully funded mission to prevent, treat and cure the diseases that plague every American family. Today, I cry out for unity regarding the efforts of the ACC which can bring healing wholeness and perhaps a bond of peace. We are all diverse families sharing this small planet and we all want the same thing: healthy longevity. The ACC is unequivocally the right solution to confront the nation’s health crisis and the plan is already in place. Right now, we need only to act on it by uniting our hearts, hope, and hands in active support with quick fire momentum to result in an epic unified outcome. Let’s put these disease groups out of business. Too many families have been desperate for far too long. It’s time for prevention, cures, healing, and wholeness. Lou and Dr. Boxer have taken the position of warriors for this cause. In unity, let’s put our hands to the plow with them and burst open the doors for The American Center for Cures. I’ve often heard it said, ‘how good and pleasant it is for brothers to dwell together in unity.’ I see only one other place where we as families strive with greater unity, and that place is in love. We can do this, together. We are family. We are unity strong.” The ACC initiative was introduced by co-founders Lou Weisbach and Dr. Rick Boxer, who was recently appointed by President Joseph Biden to the National Cancer Advisory Board. Their tireless, exemplary, and passionate efforts will enable us to turn theory into practice and finally make the families of our nation and the world recipients of long-awaited prevention, treatments, and cures through fully funded mission-based entities in the private sector individually focused on major diseases with CEO’s that are accountable and responsible to finally get the job done. Former Secretary of Health Tom Price commented that, “when this plan is approved it will rival the greatest achievements in US history and offer the sense of urgency that all American families yearn for and deserve when battling disease.” Ms. Sledge, who is also an ordained minister, and the ACC CEO Lou Weisbach are available for interviews to personally discuss this bipartisan initiative and its mission to unite medicine, science, pharmaceuticals, business, and government to seek out new treatments and cures for Alzheimer’s, diabetes, Parkinson’s, mental diseases, many forms of cancer, and several others. You can listen to “Unity Strong,” Ms. Sledge’s new song dedicated to mission of the ACC, here. About American Center for Cures The American Center for Cures (ACC) initiative is a bipartisan mission to prevent, treat and cure diseases that plague every American family. The initiative will be funded by the sale of $750B bonds by the Federal Reserve, providing the capital needed to accelerate the current trajectory of medicine. Annual interest will be paid through the licensing of new compounds and drugs to pharmaceutical companies. The principal will be repaid by savings provided to the United States Government through successes in the areas of prevention and cures. The ACC business model will cost the government and taxpayers nothing, making this the single most impactful investment on behalf of the American people in the nation’s history. For more information, please visit https://theamericancenterforcures.org. Contact Details Jenna Beaucage +1 508-340-6851 jbeaucage@rainierco.com Company Website https://theamericancenterforcures.org

March 23, 2023 08:15 AM Eastern Daylight Time

CleverTap Gaming Unveiled at GDC 2023

CleverTap

CleverTap, the all-in-one customer engagement platform, today at Game Developers Conference 2023 unveiled CleverTap Gaming – soon to go live in the summer of 2023. Through full player management, the latest offering will help boost revenue from LiveOps, Lifecycle Marketing, and Remote Configuration by 3x with personalization across the entire player journey. The platform is powered by TesseractDB™, CleverTap's proprietary data engine, which is built for real time triggering & segmentation with high performance, low latency, and massive economies of scale. CleverTap Gaming brings holistic and sophisticated multi-channel campaigns inside and outside the in-game experience. With a simplified UI, it reduces the dependence on technical teams and increases operational efficiency. By leveraging CleverTap’s proprietary TesseractDB™, it offers rich granularity with unlimited data points and no restrictions on lookback period. Previously, the lack of these features could have been a limiting factor for game studios trying to maximize retention and lifetime value, but CleverTap Gaming unlocks these use cases enabling game studios to scale their personalization efforts to new heights. Also, given its versatility, CleverTap Gaming offers a vast array of benefits within various functions in typical game studios: LiveOps: With over 2000 unique player attributes (10x more than the industry average), LiveOps Managers can improve the relevance of their offers with much more granular insights into user behavior and preferences. Marketing: Consumers have vastly different preferences and a single journey does not fit each and every one of them. As such, conditional logic, advanced branching, and unified composition flow across all channels can help marketers plan campaigns with contingencies in mind. The advanced segmentation feature can also help marketers create better-targeted campaigns from the outset. Development: The ability to integrate with existing backend solutions lowers the barrier to transition for gaming studios with other solutions. Native Unity SDK means the platform can enhance developer productivity and shorten release cycles considerably. “Modern gaming is evolving. They are no longer static endpoints – and with features like LiveOps and Remote Configuration, developers are empowered to make changes in real-time without the constraints of approvals and a relaunch.” said Lawrence Hsieh, Principal Product Manager at MobilityWare. “CleverTap Gaming gives us an all-in-one cost-effective solution that ensures consistency and efficiency while not only developing but also promoting an update.” “With over 2.6 billion mobile game players globally, it is only a matter of time before the growth trajectory flattens out and retention becomes a bigger area of focus. We hope that CleverTap Gaming can accompany those studios looking to stay ahead of the curve by maximizing their pre-existing user base via personalized and relevant messaging,” said Sunil Thomas, Co-founder and Executive Chairman at CleverTap. “When we acquired Leanplum last year, we looked to strengthen our footprint within various verticals and geographies. CleverTap Gaming is another step in this direction, and we are confident that it will further accelerate our growth journey.” About CleverTap Gaming, powered by Leanplum CleverTap Gaming is powered by Leanplum and helps gaming studios achieve engagement and revenue goals by providing the tools and expertise to deliver more personalized player experiences at scale. Learn more about what CleverTap can do for your brand at clevertap.com. For a platform demo, visit clevertap.com/live-product-demo/ About CleverTap CleverTap is the all-in-one customer engagement platform that helps brands personalize and optimize all consumer touch points to improve user engagement, retention, and lifetime value. It's the only solution built to address the needs of retention and growth teams, with audience analytics, deep-segmentation, multi-channel engagement, product recommendations, and automation in one unified product. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering both speed and economies of scale. CleverTap is trusted by 2000 customers, including Electronic Arts, TiltingPoint, Gamebasics, Big Fish, MobilityWare, TED, English Premier League, TD Bank, Carousell, AirAsia, Papa Johns, and Tesco. Backed by leading investors such as Sequoia India, Tiger Global, Accel, and CDPQ the company is headquartered in Mountain View, California, with presence in San Francisco, New York, São Paulo, Bogota, London, Amsterdam, Sofia, Dubai, Mumbai, Singapore, and Jakarta. For more information, visit clevertap.com or follow on LinkedIn and Twitter. Forward-Looking Statements Some of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release. Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction. Contact Details Sony Shetty sony@clevertap.com Company Website https://clevertap.com/

March 23, 2023 04:45 AM Eastern Daylight Time

1 ... 51 52 53 54 55 ... 151